Elevating Medicinal Cannabis Storage

In the dynamic landscape of medicinal cannabis, the importance of impeccable storage solutions cannot be overstated. At BS3, we recognize the critical role that proper storage plays in maintaining the quality of medicinal cannabis pharmaceuticals. Our state-of-the-art storage facilities are meticulously designed to meet and exceed industry standards, providing a secure environment that safeguards the potency and purity of every product.

2024-02-21T14:31:03+10:30February 21, 2024|

Elevating Excellence: BS3’s Journey of Continued Growth in Pharmaceutical Storage Solutions

As a company dedicated to delivering the highest standards of service for specialised pharmaceutical storage & distribution solutions, we are proud to be able to announce that BS3’s strong growth continues.  With our newest state-of-the-art Schedule 8/9 pharmaceutical storage vault commissioned mid 2023 already at 75% capacity, we are thrilled to unveil that a third vault is now currently under construction.

2023-08-31T15:15:12+10:30August 31, 2023|

Understanding the importance of Ultra-Low Temperature (ULT) freezer technology storage

Ultra-low temperature (ULT) freezers are an absolute necessity for any organization handling temperature-sensitive specimens, therapies or mRNA vaccines. This essential cold storage equipment can effectively and safely preserve the cold chain for pharmaceutical, biotechnology, life sciences and healthcare industries. With the recent ultracold temperature requirements of mRNA-based COVID-19 vaccines, ULT cold storage has become a key focus for vaccine storage and distribution. Here are some best practices for understanding ULT freezer technology and its important connection to the logistics of last-mile delivery of temperature-sensitive medicines and vaccines.

2023-07-27T15:02:41+10:30July 27, 2023|

Setting Ourselves Apart, the BS3 Boutique Storage Specialists’ Approach

In a competitive pharmaceutical storage market, differentiation is essential for success. At BS3 Pharmaceutical Storage & Distribution Specialists, we set ourselves apart by offering customized solutions, prioritizing long-term partnerships, upholding ethical business practices, and delivering unmatched value. Our focus is on meeting our clients' unique needs and exceeding their expectations rather than engaging in ruthless competition or catering to the highest bidder. By choosing BS3 Boutique Storage Specialists, clients can rest assured that they are partnering with a reliable and trustworthy provider that has their best interests at heart

2023-06-27T23:33:50+10:30June 13, 2023|

GDP & it’s Vital Role in the Storage & Distribution of Clinical Trial Materials

Clinical trials are an important part of the drug development process, requiring careful planning and execution to ensure the safety and efficacy of the drugs being tested. Good Distribution Practices (GDP) is an essential part of this, guaranteeing quality standards and guidelines govern the storage, transportation, and distribution of pharmaceutical products.

2023-06-27T23:33:55+10:30May 17, 2023|

Exciting BS3 Growth Update

We are thrilled to share that due to continued strong growth in demand, BS3 is embarking on the next phase of expansion and proudly announce the launch of our next state-of-the-art pharmaceutical Schedule 8/9 vault.  This new vault not only expands our storage capabilities but also enhances the security and protection of your valuable assets. As a company dedicated to delivering the highest standards of service, we recognize the need for specialised storage solutions.  Our Pharmaceutical Schedule 8/9 Vault has been designed with cutting-edge security features and advanced technology. 

2023-06-27T23:34:20+10:30May 16, 2023|

Understanding the upcoming changes to MDMA & Psilocybin access

3rd February 2023, the Therapeutic Goods Administration (TGA) announced that from the 1st July 2023, medical use of MDMA and Psilocybin will be rescheduled from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines) of the Poisons Standard. Which will enable authorised psychiatrists to prescribe these substances for treatment-resistant depression and treatment resistant post-traumatic stress disorder.

2023-07-27T14:55:38+10:30April 19, 2023|

MDMA & Psilocybin to be rescheduled from S9 to S8

3rd February 2023, the Therapeutic Goods Administration (TGA) announced that from the 1st July 2023, medical use of MDMA and Psilocybin will be rescheduled from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines) of the Poisons Standard. Which will enable authorised psychiatrists to prescribe these substances for treatment-resistant depression and treatment resistant post-traumatic stress disorder.

2023-03-20T14:24:54+10:30February 10, 2023|
Go to Top